Stroke Recovery: Can You Safely Take Ambien?

Ambien, also known as zolpidem, is a popular sleeping pill that has been approved by the U.S. Food and Drug Administration (FDA) for treating insomnia. Recent studies have suggested that Ambien may also aid in stroke recovery. In experiments with mice, researchers found that low doses of Ambien helped speed up the rodents' recovery from strokes, improving their sensory acuity and motor coordination. This has led to speculation about whether Ambien could be used to help human stroke patients recover more quickly. However, it is important to note that Ambien has also been associated with an increased risk of ischemic stroke, and some users have experienced adverse side effects.

Ambien's effect on stroke recovery in mice

A 2015 study by researchers at Stanford University School of Medicine found that mice that had strokes rebounded significantly faster if they received low doses of Ambien, a popular sleeping aid. The study, led by Gary Steinberg, MD, PhD, professor and chair of neurosurgery, was published in the journal Brain.

According to the study, Ambien, also known by its trade name Zolpidem, increased the rate at which mice that had strokes recovered their pre-stroke sensory acuity and motor coordination. Mice that were given Ambien recovered their stroke-impaired ability to notice and remove a piece of tape stuck to their paw within a few days of treatment, while mice that were not given the drug took about a month to fully recover this ability.

The researchers attributed Ambien's effectiveness to its enhancement of nerve-cell signaling activity, specifically the increase in signalling by the GABA neurotransmitter in parts of the brain that are able to rewire themselves. Before this study, it was believed that GABA signaling after a stroke was detrimental. However, the Stanford study showed that if it's the right kind of GABA signaling, it can be beneficial.

While the results of the study are promising, Steinberg cautioned that the results need to be independently replicated in other laboratories before clinical trials of the drug's capacity as a stroke-recovery agent can begin. Furthermore, while Ambien improved the rate of recovery in mice, its ability to increase the extent of their recovery couldn't be determined because, unlike humans, mice naturally regain most of their pre-stroke function eventually. Therefore, the researchers intend to test the drug in other animal models and experiment with different doses and timing before proceeding to clinical trials.

Ambien's potential to increase the GABA neurotransmitter

Ambien, also known as zolpidem, is a sedative-hypnotic drug that acts on GABA-A receptors. It is primarily used as a sleeping aid to treat insomnia and has been approved by the US Food and Drug Administration (FDA).

Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a crucial role in the brain and nervous system. It is the most common inhibitory neurotransmitter in the central nervous system, which comprises the brain and spinal cord. By binding to GABA-A and GABA-B receptors, GABA prevents or blocks chemical messages and reduces the stimulation of nerve cells. This inhibitory function is essential for controlling nerve cell hyperactivity associated with anxiety, stress, and fear.

Zolpidem's mechanism of action involves enhancing synaptic GABA signaling. It has a higher affinity for synapse-associated GABA-A receptors than extrasynaptic receptors. By increasing the activity of GABA at these receptors, zolpidem can amplify the inhibitory effects of GABA, leading to a calming influence on the nervous system. This is particularly relevant in the context of stroke recovery, where GABA signaling has been implicated.

In a study conducted by researchers at Stanford University School of Medicine, zolpidem was found to improve stroke recovery in mice. The study induced two types of strokes in mice: one affecting sensory abilities and the other impairing movement. The mice treated with low doses of zolpidem, below the threshold for sedation, exhibited faster recovery of their sensory and motor functions compared to the control group. This finding suggests that zolpidem's enhancement of synaptic GABA signaling may play a beneficial role in stroke recovery.

While the study provides promising insights, further research is needed before clinical trials can be initiated. The researchers emphasize the necessity of replicating the results in other laboratories to establish the efficacy and safety of zolpidem for stroke recovery in humans. Nonetheless, the potential of zolpidem to increase GABA signaling offers a new direction in the search for treatments to improve stroke recovery.

Ambien's side effects

Ambien, also known as zolpidem, is a popular sleeping aid that has been approved by the U.S. Food and Drug Administration (FDA) for treating insomnia. While it has shown promising results in aiding stroke recovery in mice, its side effects in humans have raised concerns.

Firstly, a 2013 study in Taiwan found that exposure to zolpidem was associated with an increased risk of ischemic stroke. The risk increased with higher exposure to the drug, and it was present regardless of whether individuals had a sleep disorder. This finding warrants further large-scale investigations to fully understand the relationship between zolpidem use and stroke risk.

In addition, Ambien has been linked to several adverse effects in humans. In 2013, the FDA lowered the recommended dose due to concerns that it made some users too drowsy to drive safely the following morning. There have also been reports of users engaging in activities such as eating, texting, or even driving, with no memory of it the next morning. This phenomenon, known as "complex sleepwalking," has raised safety concerns about the use of Ambien.

Furthermore, almost 20,000 visits to emergency departments in 2010 were a result of adverse reactions to zolpidem. While rare, there have been instances of Ambien exhibiting a miraculous power to wake people from a minimally conscious state, with increased ability to move, respond to commands, and attempt to communicate for a short period after taking the drug. However, these responses have been observed in only a small number of cases.

In conclusion, while Ambien has shown potential in aiding stroke recovery, its side effects cannot be overlooked. It is important to carefully weigh the benefits against the risks when considering the use of Ambien, especially in individuals who have experienced a stroke or are at risk of stroke. Further clinical trials and large-scale studies are necessary to fully understand the effects of this drug.

Ambien's use in treating insomnia

Ambien, also known as zolpidem, is a sedative or hypnotic drug used to treat insomnia. It is available as an immediate-release tablet to help people fall asleep and an extended-release form, Ambien CR, which helps people stay asleep. Zolpidem affects the brain's chemicals, which may be unbalanced in people with insomnia. It is a non-benzodiazepine hypnotic agent that works like a gamma-aminobutyric acid (GABA) agonist. GABA is an inhibitory neurotransmitter that helps the body and mind relax, fall asleep, and increase sleep continuity. Low GABA activity is linked to insomnia and disrupted sleep.

Ambien is a short-acting drug, and its use should be determined by a doctor. It is not approved for use by anyone younger than 18 years old and is only recommended for short-term use. The recommended dose is either 5mg or 10mg, taken once daily at bedtime, allowing for at least seven hours of sleep before awakening. The dose may differ for females and males, as clearance is lower in females. Older people may also be more sensitive to the effects of zolpidem, and the recommended dose for this demographic is 5mg once daily, taken before bedtime.

Side effects of taking Ambien may include daytime drowsiness, dizziness, weakness, a tired feeling, loss of coordination, a stuffy nose, dry mouth, nausea, constipation, and diarrhea. It is important to note that Ambien may impair thinking or reactions, and users should refrain from activities that require them to be awake and alert, such as driving or operating machinery. Additionally, Ambien may cause a severe allergic reaction, and users should seek emergency medical help if they experience hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

While Ambien is a popular treatment for insomnia, it is not without controversy. In 2013, the FDA lowered the recommended dose due to concerns about drowsiness affecting users' ability to drive safely. There have also been reports of users engaging in activities such as driving, eating, walking, making phone calls, or having sex with no memory of doing so the next morning. As a result, Ambien is potentially habit-forming, and misuse can lead to addiction, overdose, or even death. Therefore, it is essential to follow the prescribed dosage and duration of use as instructed by a doctor.

Ambien's effect on blood circulation to the brain

Ambien, also known as zolpidem, is a sedative or hypnotic drug that acts on chemicals in the brain that may be unbalanced in people with sleep problems (insomnia). It is a short-acting imidazopyridine hypnotic that binds to the benzodiazepine binding site on specific GABAA receptors to enhance fast inhibitory neurotransmission. By increasing GABA-mediated inhibition, Ambien can induce sleep and reduce brain activity in certain regions.

Effect on Blood Circulation

While the primary purpose of Ambien is to induce sleep, it also has effects on cerebral blood flow and circulation to the brain. Some studies have shown that Ambien can increase regional cerebral blood flow, particularly in the occipital cortex and parietal and occipital cortices. This increase in blood flow to the brain may be due to the drug's effect on vascular tone within the brain, leading to vasodilation and increased blood flow.

However, other studies have found that Ambien can reduce cerebral blood flow and glucose metabolism, particularly in frontal regions such as the frontal cortex, white matter, anterior cingulate, basal ganglia, insula, and hippocampus. This reduction in blood flow and metabolism may be related to the drug's inhibitory effects on neuronal activity, as inhibition is an active process that requires glucose and oxygen consumption. Additionally, the increase in resting cerebral blood flow caused by Ambien may lead to a subsequent decrease in the blood-oxygen-level-dependent (BOLD) signal during functional magnetic resonance imaging (fMRI) tasks.

Effect on Stroke Recovery

The effect of Ambien on blood circulation to the brain has implications for stroke recovery. Strokes occur when the blood supply to part of the brain is blocked, leading to tissue damage and death. While there are treatments available to clear the blockage, they must be initiated within a few hours of the stroke's onset to be effective. As a result, less than 10% of stroke patients benefit from these treatments.

Ambien has been found to enhance stroke recovery in mice, with treated mice recovering their sensory acuity and motor coordination faster than those given a placebo. This effect is believed to be due to Ambien's impact on GABA signaling, a neurotransmitter that plays a role in recovery. However, it is important to note that Ambien has also been associated with an increased risk of ischemic stroke in some population-based studies.

In summary, Ambien (zolpidem) has complex effects on blood circulation to the brain, with studies showing both increases and decreases in cerebral blood flow and metabolism in different regions of the brain. While it has shown promise in enhancing stroke recovery in animal models, more research is needed to fully understand its effects on the brain and its potential benefits and risks for stroke patients.

Frequently asked questions